UPFRONT BRIEFING
Sanofi is shopping for life after Dupixent, and Insmed is in the cart. Bloomberg says the French drugmaker is working with advisers on a possible bid for the Brinsupri maker, a roughly $26B company before anyone talks premium. Nothing is signed. Across the Channel, Novartis rolled its growth target forward to 5% a year through 2031 and told London it doesn't need a big deal to get there.
Washington chimed in too: a congressional commission warned that China-sourced licensing is tilting toward the Chinese side of the table. On the calendar, the EORTC-NCI-AACR (ENA) symposium is under way in Barcelona, with Erasca presenting ERAS-0015 pan-RAS data today, and Capricor's deramiocel PDUFA lands Sunday (22 Nov).
TAPE ACTION

Healthcare fell with the market: XLV (2.0%) matched the S&P 500 (2.0%), with Merck (3.6%) among the heavyweights lower, while small- and mid-cap biotech lost less, XBI (0.6%) and NBI (1.0%), and BBC finished flat. Single names: Insmed +20.6% after a midday Bloomberg report of Sanofi takeover interest, and Novartis (2.6%) after its mid-term guidance reset.
Anthropic's debut didn't rescue AI stocks. It priced at $83, opened at $111.50 and closed at $97.17 (+17.1%), while Nvidia (3.3%) fell for a sixth straight session and AMD (7.7%) dropped after Hunterbrook disclosed a short. The Dow fell (2.2%), 1,101 points, to 49,097, the S&P 500 (2.0%) posted its sixth straight loss and the Nasdaq 100 fell (2.2%). Philly Fed slumped to 6.3 against 18 expected, jobless claims came in at 203k, and CME prices a 96% chance of a December hike.
THE BIG 3
1️⃣ — Sanofi weighs a bid for Insmed and its Brinsupri franchise
Bloomberg reported Thursday morning ET that Sanofi is working with advisers on a potential acquisition of Insmed. Deliberations are ongoing, any deal could be weeks away, and neither company commented. INSM closed +20.6% at $144.46 after a brief volatility halt, valuing Insmed at roughly $26B; SNY fell 2.3%.
Why it matters: An Insmed deal would be close to three times the $9.5B Sanofi paid for Blueprint in 2025, and that's before a premium on a stock that just added a fifth. Brinsupri is the prize: Q3 sales were $400.1M, up 29% on Q2, and 2026 guidance was lifted to $1.35-1.40B for the first approved therapy in non-CF bronchiectasis, a lung franchise next to Dupixent's COPD and asthma business. The catch is the entry price. A 20.6% one-day jump bakes in a bid nobody has confirmed, Bloomberg says any deal could be weeks away, and Brinsupri's quarterly growth has already cooled from 44-49% to 29%.
Source: Endpoints
More: Fierce Pharma; Proactive
2️⃣ — Novartis resets to 5% growth through 2031, no big deals assumed
At Meet Novartis Management in London, Novartis set a +5% cc sales CAGR for 2026-2031 (the prior range was 5-6% for 2025-2030) and kept its 40%+ core margin target for 2029. It raised peak-sales guidance for Kesimpta ($8B from $6B), Scemblix and Leqvio ($5B each from $4B), after Rhapsido's recent move to $8B. NVS fell 2.6% to $151.22.
Why it matters: The 5% target is the low end of last year's 5-6% range rolled forward a year, and consensus already sat near 4.5%, so the 2.6% drop is about what comes after 2031. Fierce sizes the post-2030 patent cliff at $16.7B. Entresto generics are costing roughly $4B of sales this year, and Kisqali and Cosentyx face pricing pressure late in the decade. Novartis says the plan assumes no large acquisitions, a pointed line after late-stage misses, including del-desiran from the $12B Avidity buy, drove a $2.2B Q3 writedown. The case now rests on 35+ submission-enabling readouts through 2031, led by abelacimab in AF, ianalumab in lupus and pelabresib.
Source: Endpoints
More: Fierce Pharma; Novartis 6-K
3️⃣ — Congressional panel warns China licensing deals now favour Chinese biotechs
The National Security Commission on Emerging Biotechnology said US-China licensing deals are moving earlier, often preclinical, and toward multi-asset and platform co-development terms that favour Chinese licensors. It tied this to Beijing's September 2026 plan to produce a quarter of the world's first-in-class drugs by 2030. Separately, the House Select Committee on China said Merck, Lilly, AbbVie, Pfizer and BMS will not open new trial sites at PLA-linked hospitals or in Xinjiang.
Why it matters: Nothing binding passed, so this is a risk flag rather than a catalyst, but it lands mid-boom. China-origin assets were 39% of 2026 licensing deals and two-thirds of $245B in headline value on BioBucks' count. Pfizer signed its $330M-upfront Starna in vivo CAR-T pact this week, and Arcera took Innogen's GLP-1 abroad on Thursday. Even Novartis CEO Vas Narasimhan used his own investor day to call for a COINS Act adjustment. The commission's knowledge-transfer framing is the argument that turns a licence into a CFIUS-style review question, and its CHIPS Act lineage shows the playbook. The trial-site pledges cost the five companies little today; the precedent for sourcing diligence is what lasts.
Source: Endpoints
More: BioPharma Dive; STAT; Fierce Biotech
EVERYTHING ELSE THAT BROKE
Revolution Medicines: Rasonque + gemcitabine/nab-paclitaxel in 1L metastatic PDAC (n=61, 18.3-mo follow-up) posted confirmed ORR 60.7%, median PFS 12.8 months and 12-month OS 76.6% in an ENA late-breaker. — GlobeNewswire
Celldex: barzolvolimab missed the primary itch endpoint (PP-NRS, week 16) in a 131-patient Phase 2 in atopic dermatitis, and AD is dropped; the 2027 CSU BLA stays on track. Bausch + Lomb's BL1332 also flopped in Phase 2 for post-surgical ocular pain, though the company still wants Phase 3 talks. — Fierce Biotech
Actinogen: Xanamem (emestedastat) failed the 247-patient Phase 2b/3 XanaMIA Alzheimer's trial, with a non-significant 0.10-point benefit at week 36, and the stock fell about 80%. — BioSpace
Lilly broke ground on its $3.5B Lehigh Valley, Pennsylvania plant for obesity drugs including retatrutide. — Endpoints
Evaxion: halting infectious-disease and autoimmune R&D to focus solely on cancer vaccines. — Fierce Biotech
DEAL FLOW
Track the Deals Shaping Biotech
Track M&A, licensing agreements, IPOs and venture financings. Explore deal values, key terms and transaction details in our regularly updated BioBucks trackers.
M&A / BD&L
Sanofi / Insmed: Sanofi is weighing a takeover, per Bloomberg. The report is unconfirmed, no terms, and Insmed is valued at ~$26B. — Fierce Pharma
Merck / Isomorphic Labs: research collaboration on small molecules for one undisclosed oncology target; upfront and milestones undisclosed, tiered royalties, and an Isomorphic option to co-fund development for higher royalties. — STAT
AbbVie / DISCO Pharmaceuticals: option deal on AND-gated bispecifics for solid tumors from DISCO's surface-target platform, $40M upfront, up to $2.54B. — Endpoints
Arcera / Innogen: exclusive rights to China-approved GLP-1 efsubaglutide alfa in parts of Africa, Eastern Europe, Latin America and the Middle East; $15M upfront ($38M with near-term milestones), more than $1B total, royalties up to double digits. — RTTNews
VC / PRIVATE FINANCINGS
MegaRobo (China): nearly $200M (round undisclosed) for AI lab automation, Oman Investment Authority-backed, joined by Asia Investment Capital, Granite Asia, Sinovation Ventures and CMB International; ~$600M raised to date. — Endpoints
IPO / FOLLOW-ON
No notable biotech IPOs or follow-ons priced since yesterday's edition.
ACADEMIC CORNER
Nature Medicine detailed multicenter enterocolitis findings after BCMA-directed CAR-T therapy, with just 32% resolved at last follow-up. — Nature Medicine
Nature Medicine profiled mucosal CAR+ T-cell expansion in BCMA CAR-T-associated enterocolitis with a cytotoxic, clonal phenotype. — Nature Medicine
Lancet examined whether remibrutinib could emerge as a high-efficacy disease-modifying option in relapsing multiple sclerosis. — Lancet
Know someone who'd like this?
Forward it along. It takes ten seconds and means a lot to us.
Sanofi's browsing a $26B basket. We're just browsing the weekend.
— The BioBucks Team
